Adaptimmune Therapeutics PLC Balance Sheet
ADAPY|9 years of annual SEC 10-K data (FY2016-FY2024)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 9 fiscal years. All figures from audited SEC 10-K filings.
Adaptimmune Therapeutics PLC had $246M in total assets and $12M in shareholders' equity as of FY2024. Total debt was $54M against $91M in cash, resulting in a $37M net cash position.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -3.53 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $91.1M | $144.0M | $108.0M | $149.9M | $56.9M | $50.4M | $68.4M | $84.0M | $158.8M |
| Accounts Receivable | $1.5M | $821.0K | $7.4M | $752.0K | $139.0K | - | $192.0K | $206.0K | $1.5M |
| Inventory | $7.3M | - | - | - | - | - | - | - | - |
| Current Assets | $188.2M | $207.6M | $255.4M | $415.5M | $398.2M | $120.5M | $231.1M | $230.2M | $198.8M |
| PP&E (Net) | $31.3M | $50.9M | $53.5M | $30.5M | $27.8M | $31.1M | $36.1M | $40.7M | $27.9M |
| Total Assets | $246.0M | $282.6M | $328.9M | $469.5M | $451.1M | $181.5M | $276.7M | $281.1M | $234.5M |
| Current Liabilities | $64.5M | $72.8M | $64.5M | $62.5M | $39.1M | $34.3M | $24.4M | $74.3M | $40.3M |
| Total Debt | $54.3M | - | - | - | - | - | - | - | - |
| Shareholders' Equity | $11.8M | $39.5M | $81.9M | $206.0M | $341.2M | $123.6M | $246.9M | $203.0M | $166.1M |